{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:20:08Z","timestamp":1794745208536,"version":"4.9.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119926","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:29:03Z","timestamp":1789468143000},"page":"119926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunopeptidomics-guided cancer vaccine design: Advances, challenges, and emerging opportunities"],"prefix":"10.1016","volume":"204","author":[{"given":"Mohammad Mahdi","family":"Behzadifar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Shadkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Mirsamiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Hoseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Nickho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4785-2759","authenticated-orcid":false,"given":"Rasoul","family":"Baharlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/mcp.TIR119.001641","article-title":"Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligands","volume":"19","author":"Solleder","year":"2020","journal-title":"Mol. Cell Proteom."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119926_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","article-title":"Mass spectrometry-based antigen discovery for cancer immunotherapy","volume":"41","author":"Bassani-Sternberg","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.37349\/etat.2024.00249","article-title":"Immunopeptidomics in the cancer immunotherapy era","volume":"5","author":"Pongcharoen","year":"2024","journal-title":"Explor. Target. Anti-Tumor Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/ijms25010196","article-title":"Molecular characteristics, functional definitions, and regulatory mechanisms for cross-presentation mediated by the major histocompatibility complex: a comprehensive review","volume":"25","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6382","key":"10.1016\/j.biopha.2026.119926_bib10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.immuni.2019.08.012","article-title":"Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction","volume":"51","author":"Abelin","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/prca.70018","article-title":"Artificial intelligence and the evolving landscape of immunopeptidomics","volume":"19","author":"Vo","year":"2025","journal-title":"Proteom.Clin. Appl."},{"key":"10.1016\/j.biopha.2026.119926_bib14","series-title":"Seminars in immunology","article-title":"The impact of immunopeptidomics: From basic research to clinical implementation","author":"Shapiro","year":"2023"},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-025-01069-1","article-title":"HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design","volume":"10","author":"Kessler","year":"2025","journal-title":"npj Vaccin."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100563","article-title":"Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry","volume":"22","author":"Phulphagar","year":"2023","journal-title":"Mol. Cell Proteom."},{"issue":"7","key":"10.1016\/j.biopha.2026.119926_bib18","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.immuni.2023.05.009","article-title":"HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery","volume":"56","author":"Stra\u017ear","year":"2023","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100825","article-title":"optiPRM: a targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material","volume":"23","author":"Salek","year":"2024","journal-title":"Mol. Cell. Proteom."},{"issue":"12","key":"10.1016\/j.biopha.2026.119926_bib20","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1074\/mcp.O115.052431","article-title":"Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry","volume":"14","author":"Caron","year":"2015","journal-title":"Mol. Cell Proteom."},{"issue":"8","key":"10.1016\/j.biopha.2026.119926_bib21","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1074\/mcp.M115.055103","article-title":"Systematic errors in peptide and protein identification and quantification by modified peptides","volume":"15","author":"Bogdanow","year":"2016","journal-title":"Mol. Cell Proteom."},{"issue":"21","key":"10.1016\/j.biopha.2026.119926_bib22","doi-asserted-by":"crossref","first-page":"eadv6445","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119926_bib23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.71156","article-title":"A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines","volume":"11","author":"Feola","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.biopha.2026.119926_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2026.101478","article-title":"Integrating immunopeptidomics with liquid biopsy for precision oncology","volume":"110","author":"Masmoudi","year":"2026","journal-title":"Mol. Asp. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cll.2011.07.004","article-title":"Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification","volume":"31","author":"Whiteaker","year":"2011","journal-title":"Clin. Lab. Med."},{"issue":"14","key":"10.1016\/j.biopha.2026.119926_bib26","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.3390\/cancers13143408","article-title":"Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy","volume":"13","author":"Peltonen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119926_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835454","article-title":"Accurate MHC motif deconvolution of immunopeptidomics data reveals a significant contribution of DRB3, 4 and 5 to the total DR immunopeptidome","volume":"13","author":"Kaabinejadian","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib28","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1038\/s41467-024-48322-0","article-title":"Fragment ion intensity prediction improves the identification rate of non-tryptic peptides in timsTOF","volume":"15","author":"Adams","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","article-title":"Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes","volume":"11","author":"Chong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119926_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662443","article-title":"An integrated genomic, proteomic, and immunopeptidomic approach to discover treatment-induced neoantigens","volume":"12","author":"Olsson","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119926_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1567584","article-title":"Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections","volume":"16","author":"Tavassoli Razavi","year":"2025","journal-title":"Front. immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12985-026-03072-x","article-title":"Design and computational evaluation of a prophylactic and therapeutic multi-epitope vaccine candidate against cervical cancer","volume":"23","author":"Emadi","year":"2026","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib33","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/cancers12061660","article-title":"Uncovering the tumor antigen landscape: what to know about the discovery process","volume":"12","author":"Feola","year":"2020","journal-title":"Cancers"},{"issue":"6230","key":"10.1016\/j.biopha.2026.119926_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.biopha.2026.119926_bib35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","article-title":"Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes","volume":"37","author":"Racle","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119926_bib36","article-title":"Immunopeptidomics workflow for isolation and LC-MS\/MS Analysis of MHC Class I-bound peptides under hypoxic conditions","volume":"15","author":"Estephan","year":"2025","journal-title":"Bio-Protocol"},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12957-022-02653-8","article-title":"The impact of intraoperative radiotherapy on breast cancer: focus on the levels of angiogenic factors","volume":"20","author":"Nafissi","year":"2022","journal-title":"World J Surg Oncol."},{"key":"10.1016\/j.biopha.2026.119926_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ab.2017.12.014","article-title":"Generation and characterization of an anti-delta like ligand-4 Nanobody to induce non-productive angiogenesis","volume":"544","author":"Baharlou","year":"2018","journal-title":"Anal. biochem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/1354750X.2024.2309541","article-title":"Assessing angiogenesis factors as prognostic biomarkers in breast cancer patients and their association with clinicopathological factors","volume":"29","author":"Abbasi-Dokht","year":"2024","journal-title":"Biomarkers"},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib40","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s12029-024-01093-9","article-title":"The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody","volume":"55","author":"Afzalipour","year":"2024","journal-title":"J Gastrointest Cancer."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08923973.2018.1505907","article-title":"An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization","volume":"40","author":"Baharlou","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"17","key":"10.1016\/j.biopha.2026.119926_bib42","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2026.119926_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2026.119926_bib44","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.7150\/ijms.120868","article-title":"Advances in tumor antigen vaccines: a new frontier in cancer immunotherapy","volume":"22","author":"Feng","year":"2025","journal-title":"Int. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mas.21905","article-title":"Exploring the dynamic landscape of immunopeptidomics: unravelling posttranslational modifications and navigating bioinformatics terrain","volume":"44","author":"Flender","year":"2025","journal-title":"Mass. Spectrom. Rev."},{"issue":"203","key":"10.1016\/j.biopha.2026.119926_bib46","doi-asserted-by":"crossref","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I\u2013associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119926_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.764462","article-title":"Citrullinated epitopes identified on tumour MHC class II by peptide elution stimulate both regulatory and Th1 responses and require careful selection for optimal anti-tumour responses","volume":"12","author":"Symonds","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","article-title":"Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors","volume":"41","author":"Kacen","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib49","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.20892\/j.issn.2095-3941.2025.0370","article-title":"A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses","volume":"22","author":"Zhu","year":"2025","journal-title":"Cancer Biol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib50","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/vaccines13050478","article-title":"EBV vaccines in the prevention and treatment of nasopharyngeal carcinoma","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.biopha.2026.119926_bib51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cancers12030535","article-title":"Mass spectrometry-based identification of MHC-associated peptides","volume":"12","author":"Kote","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119926_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109542","article-title":"Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy","volume":"120","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib53","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.18632\/oncotarget.6960","article-title":"Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens","volume":"7","author":"Kalaora","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2026.119926_bib54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","article-title":"Identification of the cryptic HLA-I immunopeptidome","volume":"8","author":"Erhard","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib55","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry\u2013based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib56","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1038\/s41467-025-62647-4","article-title":"Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics","volume":"16","author":"Shapiro","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119926_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-026-01539-2","article-title":"Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer","author":"Nicholas","year":"2026","journal-title":"npj Precis. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/bib\/bbz051","article-title":"A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction","volume":"21","author":"Mei","year":"2020","journal-title":"Brief. Bioinforma."},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"issue":"8","key":"10.1016\/j.biopha.2026.119926_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012083","article-title":"HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry","volume":"13","author":"Bichmann","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119926_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103107","article-title":"caAtlas: an immunopeptidome atlas of human cancer","volume":"24","author":"Yi","year":"2021","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009368","article-title":"Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals","volume":"17","author":"Claeys","year":"2021","journal-title":"PLoS. Genet."},{"issue":"11-12","key":"10.1016\/j.biopha.2026.119926_bib63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14789450.2020.1881889","article-title":"A proteogenomic approach to target neoantigens in solid tumors","volume":"17","author":"Verma","year":"2020","journal-title":"Expert. Rev. Proteom."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-022-00446-5","article-title":"Cancer proteogenomics: current impact and future prospects","volume":"22","author":"Mani","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119926_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119926_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583287","article-title":"A roadmap toward the definition of actionable tumor-specific antigens","volume":"11","author":"Minati","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119926_bib67","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.4049\/jimmunol.2001409","article-title":"Integral use of immunopeptidomics and immunoinformatics for the characterization of antigen presentation and rational identification of BoLA-DR\u2013presented peptides and epitopes","volume":"206","author":"Fisch","year":"2021","journal-title":"J. Immunol."},{"issue":"6280","key":"10.1016\/j.biopha.2026.119926_bib68","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119926_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1621812","article-title":"The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches","volume":"16","author":"Racacho","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib73","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib74","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10555-021-09957-3","article-title":"The role of tumor heterogeneity in immune-tumor interactions","volume":"40","author":"Knoche","year":"2021","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"7662","key":"10.1016\/j.biopha.2026.119926_bib75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7823","key":"10.1016\/j.biopha.2026.119926_bib76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib77","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/cas.16118","article-title":"Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy","volume":"115","author":"Minegishi","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119926_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.866407","article-title":"An HLA map of the world: a comparison of HLA frequencies in 200 worldwide populations reveals diverse patterns for class I and class II","volume":"14","author":"Arrieta-Bola\u00f1os","year":"2023","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06850","article-title":"HLA major allele group frequencies in a diverse population of the Free State Province, South Africa","volume":"7","author":"Janse van Rensburg","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119926_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1686224","article-title":"Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer","volume":"17","author":"Tran","year":"2026","journal-title":"Front. Immunol."},{"issue":"7963","key":"10.1016\/j.biopha.2026.119926_bib81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.biopha.2026.119926_bib82","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119926_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482715","article-title":"Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients","volume":"15","author":"Heitmann","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119926_bib84","doi-asserted-by":"crossref","first-page":"S601","DOI":"10.1016\/j.annonc.2024.08.864","article-title":"813MO Phase I trial of a personalized multi-peptide vaccine combined with the TLR1\/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients","volume":"35","author":"Hackenbruch","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119926_bib85","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fimmu.2017.01210","article-title":"Interpreting T-cell cross-reactivity through structure: implications for TCR-based cancer immunotherapy","volume":"8","author":"Antunes","year":"2017","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib86","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ymthe.2018.02.017","article-title":"Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs","volume":"26","author":"Bijen","year":"2018","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119926_bib87","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib88","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.06.027","article-title":"Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient","volume":"65","author":"L\u00f6ffler","year":"2016","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib89","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41416-023-02197-y","article-title":"The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination","volume":"128","author":"Muehlenbruch","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"issue":"7662","key":"10.1016\/j.biopha.2026.119926_bib91","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2026.119926_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.vacun.2025.500390","article-title":"Recent update on multi-epitope vaccine development for treating breast cancer","volume":"26","author":"Nafiah","year":"2025","journal-title":"Vacunas"},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib93","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12032-025-02986-w","article-title":"Multi-epitope ligand-conjugated nanoparticles for tumor neoantigen targeting: advancing molecular precision in cancer immunotherapy","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib95","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1016\/j.ymthe.2025.05.036","article-title":"Multi-engineered T cell vaccine boosting TCR-T cell therapy enhances anti-tumor function and eradicates heterogeneous solid tumors","volume":"33","author":"Che","year":"2025","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib96","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"issue":"7738","key":"10.1016\/j.biopha.2026.119926_bib97","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119926_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1408173","article-title":"Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens","volume":"15","author":"Abou Kors","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib99","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1038\/s41467-024-54734-9","article-title":"Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines","volume":"15","author":"Kovalchik","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119926_bib100","series-title":"Seminars in immunology","article-title":"Integrating immunopeptidome analysis for the design and development of cancer vaccines","author":"Feola","year":"2023"},{"key":"10.1016\/j.biopha.2026.119926_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.945798","article-title":"Sex-specific differences in immunogenomic features of response to immune checkpoint blockade","volume":"12","author":"Scott","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119926_bib102","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3389\/fimmu.2018.01931","article-title":"Sex hormones determine immune response","volume":"9","author":"Taneja","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib103","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1074\/mcp.MR117.000024","article-title":"Methods, tools and current perspectives in proteogenomics","volume":"16","author":"Ruggles","year":"2017","journal-title":"Mol. & Cell. Proteom."},{"key":"10.1016\/j.biopha.2026.119926_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107311","article-title":"Big data and transformative bioinformatics in genomic diagnostics and beyond","volume":"134","author":"Saparov","year":"2025","journal-title":"Park. & Relat. Disord."},{"key":"10.1016\/j.biopha.2026.119926_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2025.1620572","article-title":"Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow","volume":"8","author":"Elfatimi","year":"2025","journal-title":"Front. Artif. Intell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib106","doi-asserted-by":"crossref","first-page":"8926","DOI":"10.1038\/s41467-024-53296-0","article-title":"ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2026.119926_bib107","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib108","article-title":"Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation","volume":"22","author":"Pyke","year":"2023","journal-title":"Mol. Cell Proteom."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib109","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/s41467-021-23713-9","article-title":"Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics","volume":"12","author":"Wilhelm","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2026.119926_bib110","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119926_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002927","article-title":"Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma","volume":"10","author":"Mohsen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119926_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705974","article-title":"Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia","volume":"12","author":"Nelde","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119926_bib113","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.1600808","article-title":"Unsupervised HLA peptidome deconvolution improves ligand prediction accuracy and predicts cooperative effects in peptide\u2013HLA interactions","volume":"197","author":"Bassani-Sternberg","year":"2016","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119926_bib114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119926_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.oor.2025.100767","article-title":"The role of artificial intelligence in predicting cancer immunotherapy response","author":"Bhushan","year":"2025","journal-title":"Oral. Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119926_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2026.02.003","article-title":"From prediction to precision: how immunopeptidomics advances neoantigen discovery","author":"Shapiro","year":"2026","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2026.119926_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1357217","article-title":"Personalized cancer vaccine design using AI-powered technologies","volume":"15","author":"Kumar","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119926_bib118","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","article-title":"Spatial omics and multiplexed imaging to explore cancer biology","volume":"18","author":"Lewis","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2026.119926_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1394003","article-title":"Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy","volume":"15","author":"Bulashevska","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119926_bib120","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/biology12121514","article-title":"Immunopeptidomics in the era of single-cell proteomics","volume":"12","author":"Mayer","year":"2023","journal-title":"Biology"},{"issue":"6382","key":"10.1016\/j.biopha.2026.119926_bib121","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"7738","key":"10.1016\/j.biopha.2026.119926_bib122","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119926_bib123","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ymthe.2018.02.017","article-title":"Preclinical strategies to identify off-target toxicity of high-affinity TCRs","volume":"26","author":"Bijen","year":"2018","journal-title":"Mol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:55:04Z","timestamp":1794743704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":123,"alternative-id":["S0753332226009625"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119926","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopeptidomics-guided cancer vaccine design: Advances, challenges, and emerging opportunities","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119926"}}